Month: July 2025

Introduction and Objective: Acyl-CoA synthetase long-chain family member 1 (ACSL1) is activated in macrophages by palmitate, driving foam cell formation through the CD36/FABP4/PPARδ axis. Our prior research showed that inhibiting ACSL1 reduces inflammation and alters lipid uptake, suggesting it as a therapeutic target. Here, we examined whether oral Triacsin C, a small-molecule ACSL inhibitor, can […]

Introduction and Objective: Pemvidutide is a long-acting, peptide-based GLP-1/glucagon dual receptor agonist that elicits significant reductions in body weight and serum lipids in preclinical and clinical studies. Reverse cholesterol transport (RCT) is an important process for removing excess cholesterol from peripheral tissues. Preclinical studies have suggested that glucagon may enhance the elimination of cholesterol, possibly […]

Introduction and Objective: We have discovered that verapamil inhibits pancreatic islet expression of beta cell toxic thioredoxin-interacting protein (TXNIP) and preserves beta cell function in mice and in subjects with T1D and these clinical findings have been independently validated. However, as a calcium channel blocker, verapamil has many additional effects. We therefore aimed to explore […]

Introduction and Objective: This study aimed to explore the mechanism of the dual GCGR/GLP-1R agonist mazdutide for improving liver fat accumulation compared to the GLP-1R agonist semaglutide.Methods: Mazdutide (30 nmol/kg per week) or semaglutide (30 nmol/kg every other day) was administrated subcutaneously for 8 weeks in diet-induced obesity mice to maintain a comparable level of […]

Introduction and Objective: Young adults with type 1 diabetes (T1D) have higher glycemia than other age groups, yet in this time of childbearing potential there are limited data on how the transition to adult care impacts gestational outcomes.Methods: Retrospective chart review at the Barbara Davis Center for Diabetes between 2014 and 2020 of women with […]

Introduction and Objective: Mazdutide (IBI362) is a dual agonist of GLP-1R and GCGR. Previous studies indicated that it significantly reduces serum uric acid levels in hyperuricemic rats compared to semaglutide. This study aims to further clarify the mechanism by which Mazdutide lowers uric acid in these rats.Methods: A hyperuricemia model was established in SD rats […]

Introduction and Objective: The use of electronic health records (EHR) to identify incident conditions in observational studies is growing. Health care encounters are related to health status and possibly other unobserved characteristics, which can lead to a phenomenon termed “encounter bias”. Several prior studies discussed potential encounter bias between encounter types and outcomes such as […]

Introduction and Objective: Obesity has reached epidemic proportions globally, posing a critical public health crisis. To address this, HM15275, a novel long-acting GLP-1/GIP/Glucagon triple agonist was developed, demonstrating potent weight loss and glycemic control in prior preclinical studies. The present study further investigates the effects of HM15275 on body weight and body composition over an […]

Introduction and Objective: The significance of adipose tissue macrophages (ATMs) in regulating adipose tissue function is well-established. However, our investigation revealed a previously overlooked subpopulation of macrophages adhered to adipocytes, which we term adhesion-related macrophages (ARMs).Methods: We developed a method to isolate both ARMs and non-ARMs. Molecular and functional differences were analyzed, and Cav-1 knockout […]

Introduction and Objective: Glucagon-like Peptide-1 receptor agonists (GLP1s) are comparable to insulin for the treatment of T2D and promote weight loss. There are limited data to guide GLP1 use in severely uncontrolled T2D (A1C ≥10%).Methods: We conducted a retrospective cohort study of 1,518 adults with T2D who were ordered a GLP1 or basal insulin within […]